Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488077 | SCV000574792 | likely pathogenic | not provided | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000816556 | SCV000957071 | pathogenic | Charcot-Marie-Tooth disease type 2 | 2018-11-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to be de novo in an individual affected with lipodystrophy (Invitae). This variant has also been observed in an individual affected with Hutchinson–Gilford progeria syndrome (PMID: 25001855). ClinVar contains an entry for this variant (Variation ID: 424915). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with glycine at codon 53 of the LMNA protein (p.Glu53Gly). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. |